Community Practice Connections™: Matching the Tumor With Patient-Specific Goals to Inform Frontline Selection and Sequencing in Chronic Lymphocytic Leukemia
Community Practice Connections™: Matching the Tumor With Patient-Specific Goals to Inform Frontline Selection and Sequencing in Chronic Lymphocytic Leukemia is organized by Physicians' Education Resource, LLC (PER).
Release Date: February 28, 2023
Expiration Date: February 28, 2024
Description:
One of the clinical hallmarks of chronic lymphocytic leukemia (CLL) is the high degree of variability in its disease course. Some patients experience an indolent disease, whereas others have very aggressive disease requiring treatment. Over time, however, most patients relapse and develop refractory disease resistant to standard therapies. Risk stratification and staging in CLL drive therapeutic choice and influence outcomes. Once established, therapeutic choice can range from no treatment in a low- to intermediate-risk asymptomatic patient to treatment with single agents or combinations in the high- to very high–risk group. The rapid pace and sheer volume of therapeutic developments that continue to emerge in the treatment of CLL create practical challenges for oncologists who strive to maintain cutting-edge care for their patients.
This Community Practice Connection™ program provides an in-depth review of key highlights from the Updates from the Annual Hematology Meeting: Matching the Tumor With Patient-Specific Goals to Inform Frontline Selection and Sequencing in Chronic Lymphocytic Leukemia live webcast, held in December 2022. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with CLL, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live webcast and to help reinforce learnings for those who did.
Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
- Determine the impact of risk stratification, patient-specific factors, and MRD assessment on therapeutic decisions for patients with CLL
- Assess recent clinical evidence on current and emerging therapeutic approaches that have been evaluated for the treatment of patients with CLL across lines of care
- Apply proactive strategies to recognize and mitigate toxicities associated with monotherapy and combination approaches in patients with CLL
- Translate pivotal trial data on evolving therapeutic options in CLL to develop patient-adapted treatment decisions and sequencing strategies